Loading quotes...
Forecast
| Buy |
0 |
| Hold |
2 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2022 | YoY |
|---|---|---|
| Revenue | 275.49K | 38.42% |
| Gross profit | 275.49K | 38.42% |
| Net profit | -19.87M | 36.64% |
| EBITDA | -21.88M | 30.43% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €24.67M |
Number of shares | 3.25M |
52-week high/low | €7.59 - €2.77 |
| Dividends | No |
Beta | 1.03 |
P/E ratio | -0.03 |
PEG ratio | 0.00 |
P/B ratio | 0.03 |
P/S ratio | 96.15 |
Company profile
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
| Name | Liminal BioSciences |
| CEO | Bruce Pritchard BA, CA, FIOD |
| Headquarters | Laval,
qc Canada |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 12/18/2009 |
| Employees | 251 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | LMNL |
